ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2009
Dichotomous role of interferon-gamma in allogeneic bone marrow transplant.
Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 62 citations in OpenAlex.
- Trial
- CD56Haematologica · 2017Trial
- Tissue-Based Transcriptomic Profiling of Gastrointestinal Graft Versus Host Disease Reveals Immune and MicroRNA Dysregulation.International journal of molecular sciences · 2026Article
- Allogeneic NKG2D CAR-T Cell Therapy: A Promising Approach for Treating Solid Tumors.Biomedicines · 2025Review
- AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease.Blood advances · 2024Article
- The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.Frontiers in immunology · 2024Review
- IFN-γR/STAT1 signaling in recipient hematopoietic antigen-presenting cells suppresses graft-versus-host disease.The Journal of clinical investigation · 2023Article
- HLA-E circulating and genetic determinants in schizophrenia and bipolar disorder.Scientific reports · 2021Article
- Taking the road less traveled - the therapeutic potential of CBP/β-catenin antagonists.Expert opinion on therapeutic targets · 2021Review
- Article
- Multiorgan failure with abnormal receptor metabolism in mice mimicking Samd9/9L syndromes.The Journal of clinical investigation · 2021Article
- T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?Frontiers in immunology · 2021Review
- LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host DiseaseFrontiers in immunology · 2021Article
- Cell-Penetrating Anti-Protein Kinase C Theta Antibodies Act Intracellularly to Generate Stable, Highly Suppressive Regulatory T Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.JCI insight · 2020Article
- Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease.Journal of visualized experiments : JoVE · 2020Article
- Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Article
- Individual Immune-Modulatory Capabilities of MSC-Derived Extracellular Vesicle (EV) Preparations and Recipient-Dependent Responsiveness.International journal of molecular sciences · 2019Article
- Reciprocal immuno-biological alterations occur during the co-culture of natural killer cells and adipose tissue-derived mesenchymal stromal cells.Cytotechnology · 2019Article
- MicroRNA in T-Cell Development and T-Cell Mediated Acute Graft-Versus-Host Disease.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Interferon (IFN)-gamma is a pleiotropic cytokine with a central role in innate and adaptive immunity. As a potent pro-inflammatory and antitumor cytokine, IFN-gamma is conventionally thought to be responsible for driving cellular immune response. On the other hand, accumulating evidence suggests that IFN-gamma also has immunosuppressive activity. An important role for IFN-gamma in inhibiting graft-versus-host disease (GVHD) has been demonstrated in murine models, despite IFN-gamma being one of the key factors amplifying T cell activation during the process of acute GVHD (aGVHD), the major complication and cause of post-transplant mortality in allogeneic bone marrow transplantation (BMT). At the same time, IFN-gamma facilitates graft-versus-leukemia (GVL) activity. Dissociation of GVL effects from GVHD has been the ultimate goal of allogeneic BMT in the treatment of hematologic malignancies. This paradoxic role of IFN-gamma makes modulating its activity a promising strategy to maximize GVL while minimizing GVHD and improve clinical outcomes in BMT. In this review, the effects of IFN-gamma on GVHD and GVL are discussed with consideration of the mechanism of IFN-gamma action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.